TLX250-302

A Phase 3, Randomized, Multi-Center, Open-Label Study to Compare 177Lu-TLX250 (177Lu-DOTA-girentuximab) with the Investigator’s Choice of a Single Agent Therapy in Participants With Carbonic Anhydrase 9 (CAIX) Expressing, Advanced Relapsed or Recurrent Clear Cell Renal Cell Carcinoma (ccRCC).

Enquire

Trial overview

Clinical Area

Theranostics

Disease

Kidney

Disease site

Genitourinary (GU)

Study Phase

III

Trial Identifiers

Registration number: NCT07197580

https://clinicaltrials.gov/study/NCT07197580

GenesisCare Location(s)

Murdoch (St John of God Hospital)

St John of God Murdoch Hospital, 100 Murdoch Drive, Murdoch, WA, 6150, Australia

(08) 9366 1500

receptiononcologymurdoch@genesiscare.com

Find out more Get directions

Principal Investigator(s)

Nuclear Medicine Physician

Dr Aviral Singh

MD PGDipCard MSc FAfNM FRACP - Clinical Head of Theranostics and Nuclear Medicine

View Profile

How can we help?

If you have a medical emergency please call 000. If you have an urgent request and would like to speak to our staff, please contact one of our centres directly.

* Indicates a required field.

First name *

Last name *

Email *

Phone *

State *

Postcode *

What is the reason for enquiry?

How would you prefer to be contacted? *

Phone

By submitting you acknowledge we will use the information you are providing to contact you about your enquiry. For more information about how we handle your personal information, please refer to the GenesisCare Privacy Policy.

Disclaimer:

This website is provided for information purposes only. Nothing on this website is intended to be used as medical advice, or to diagnose, treat, cure or prevent any disease. It should not be used as a substitute for your own health professional's advice. Any medical procedure or treatment carries risks. Before proceeding with treatment, you should discuss the risks and benefits of the treatment with an appropriately qualified health practitioner. Individual treatment outcomes and experiences will vary.

Disclaimer: